Evaluations of the Public Health Impact of Adult Vaccination with Pneumococcal Vaccines Should Include Reductions in All-Cause Pneumonia

Clin Infect Dis. 2020 May 23;70(11):2456-2457. doi: 10.1093/cid/ciz882.

Authors

Christian Theilacker¹, Andrew Vyse^{1

2}, Luis Jodar^{1

3}, Bradford D Gessner^{1

3}

Affiliations

¹ Vaccines Medical Development and Scientific and Clinical Affairs, Pfizer Inc., Collegeville, Pennsylvania, USA.
² Pfizer Limited, Surrey, United Kingdom.
³ Pfizer Vaccines, Collegeville, Pennsylvania, USA.

PMID: 31624826
DOI: 10.1093/cid/ciz882

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Adult
Aged
Humans
Incidence
Middle Aged
Pneumococcal Vaccines
Pneumonia*
Public Health*
Retrospective Studies
Vaccination
Vaccines, Conjugate

Substances

Pneumococcal Vaccines
Vaccines, Conjugate